Groups together issues dealing with Civil Society Dialogue, EPHA collaboration with other NGOs and networks, lobbying, fund-raising etc...
Please find all related articles below.
October 2014 - In 2012, EPHA published its first ‘facts and figures’ briefing on the impacts of the economic crisis on health. Two years later, the revised and updates briefing finds that the impacts of austerity politics and economic recession continue to threaten the health and wellbeing of Europeans.
Trends in increased suicide rates, unemployment, social exclusion and unmet health needs prevail, most acutely in the newer member states and in those receiving financial (...)
A new report on medicines shortages experienced in European healthcare systems reveals that over 86% of hospital pharmacists are experiencing difficulties in sourcing medicines with 66% reporting this as a daily or weekly problem. The top affected areas are medicines to fight infection, cancer drugs and anesthetics.
Brussels, 17 November 2014 - The report by the European Association of Hospital Pharmacists (EAHP), surveyed the experiences of over 600 hospital pharmacists in 36 European (...)
Carlos Moedas (age 44) studied engineering at Lisbon University, Portugal and an MBA at Harvard University, USA. He worked for Goldman Sachs and EuroHypo investment bank before returning to Portugal in 2004 to join a property consulting company, and established his own property investment company in 2008. He led negotiations for the Social Democratic Party (PSD) for Portugal’s 2011 State Budget. He was elected as an MP in the same year, and leading implementation of the (...)
Brussels, 30 October 2014 - On 29 July 2014, the European Ombudsman opened an own-initiative inquiry towards the European Commission concerning transparency and public participation in relation to the TTIP negotiations (OI/10/2014/RA). The present public consultation concerns that inquiry.
The outcome of the TTIP negotiations could have a significant impact on the lives of citizens. The aim of the Ombudsman’s inquiry is to help ensure that the public can follow the progress of these (...)
EPHA welcomes the Commission’s publication of comprehensive consultation guidelines. Smart regulation should mean fair and citizen-centred policy making that brings tangible benefits to the citizens of Europe and improves their quality of life. This involves greater use of evidence-based impact assessment and improving the consultation process.
The aim of the guidelines should be to ensure transparency and representativeness. Publishing consultation responses, as well as explanations (...)
October 22th 2014, Brussels – The NGO signatories of this statement wholeheartedly welcome the announcement of the reversal of the decision by President-elect Jean-Claude Juncker to move the competence for pharmaceutical and medical devices to the enterprise directorate (1).
Following negotiations within the European Parliament and concerns expressed by a number of member states, President-elect Juncker stated today that the "responsibility for medicines and pharmaceutical products (...)
Health is a fundamental universal right and access to medicines is part of it. The EU and its Member States are committed to universal and equitable access to healthcare. Nevertheless, millions of European patients suffer from the lack of affordability of many life-saving medicines across Europe.
Download the event’s invitation
* See the event’s poster
An event under the auspices of MEPs Nessa CHILDERS (S&D, IE), Beatriz BECERRA BASTERRECHEA (ALDE, ES), Kostas (...)
14 October 2014, Brussels - . The European Commission’s High Level Group on Administrative Burdens (1), chaired by Dr Edmund Stoiber, has drawn severe criticism from 4 of a total of 15 Members (2) for its final report (3) pushing an outdated, deregulatory agenda.
Almost one third of ‘Stoiber group’ members oppose biased final report
The views of members representing trade unions, environmental groups, consumer organisations and health groups are presented in a (...)
October 10th 2014, Brussels – According to statements by both the S&D (1) and Green Groups (2) yesterday, it seems likely that President-elect Jean-Claude Juncker is intending to soften his decision to move pharmaceutical policy from the health portfolio to enterprise. EPHA welcomes this news as a step in the right direction and a possible cause for celebration for the European Parliament (3) and the public health community (4).
“I would like to applaud President-elect (...)
October 8 2014, Brussels - On 10th of September, the European Commission President-elected Jean-Claude Juncker unveiled the transfer of the competence for medicinal products and health technologies from the health portfolio to the enterprise one (now called Internal Market, Industry, Entrepreneurship and SMEs).
Dear Member of European Parliament,
The shift of EU pharmaceutical policy will put Europe’s security at risk and is in contradiction with how pharmaceutical policy is (...)